Treatment with the mTORC1 inhibitor everolimus, which is currently in clinical trials for T-NHL therapy (NCT00918333 and NCT01075321), reduced viability and division of PDCD1-mutant cancer cells (Fig. 7e). Here, PDCD1 is linked to non-Hodgkin lymphoma.